

# **Request for Prior Authorization**

FAX Completed Form To 1 (877) 733-3195

# Provider Help Desk I (844) 236-1464

# 

DIRECT ORAL ANTICOAGULANTS

(PLEASE PRINT – ACCURACY IS IMPORTANT)

	(PLEASE PRINT - ACCURACT IS	MPORTAINT)	
IA Medicaid Member ID #	Patient name	DC	DB .
Patient address			
Provider NPI	Prescriber name	Pho	one
Prescriber address		Fax	(
Pharmacy name	Address	Pho	one
Prescriber must complete all informa	ntion above. It must be legible, corre	ect, and complete or form	will be returned.
Pharmacy NPI	Pharmacy fax	NDC	
authorization is required for no dosing and length of therapy for recommended dose will not be indications for the requested drage for indication; and 2) Patien active bleeding; and 4) For a dia of at least one additional risk facts. A recent creatinine clearance Patient's current body weight is at a therapeutic dose with at least prescribed for the treatment of documentation patient has had molecular weight heparin or un	r submitted diagnosis. Request considered. Payment will be on the following condition to the following condition of the following conditions o	ts for doses outside of considered for FDA apions: I) Patient is with heart valve; and 3) Pastroke prevention, pate PS₂-VASc score ≥I; and recent Child-Pugh scodocumentation of a trad 9) For requests for e or pulmonary embolis with a parenteral anticonsidered so	the manufacturer proved or compendia hin the FDA labeled atient does not have cient has the presence does not be presence does not have allowed and 7) rial and therapy failure edoxaban, when sm (PE), icoagulant (low
when documented evidence is p			

Non-Preferred (PA required)			
1			
☐ Bevyxxa ☐ Savaysa			
☐ Dabigatran ☐ Xarelto Suspension			
Pradaxa Oral Packet			
Quantity Days Supply			
☐ Yes ☐ No			
Yes No			
Date obtained:	_		
Date obtained:	Date obtained:		
Date completed:	Date completed:		
	Bevyxxa Savaysa Dabigatran Xarelto Suspension Pradaxa Oral Packet  Quantity Days Supply Diagnosis:  Yes No Yes No Date obtained: Date obtained:		

### **Request for Prior Authorization DIRECT ORAL ANTICOAGULANTS**

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Risk factor based CHA<sub>2</sub>DS<sub>2</sub>-VASc Score

**Risk Factors** 

# Requests for a diagnosis of atrial fibrillation or stroke prevention:

	Congestive neart failure	'		
	Hypertension	I		
	Age ≥ 75 years	2		
	Age between 65 and 74 years	Į.		
	Stroke / TIA / TE	2		
	Vascular disease (previous MI, peripheral arterial disease or aortic plaque)	1		
	Diabetes mellitus	ı		
	Female	ı		
	To	otal		
<b>Document 2 preferred DOAC</b> Preferred DOAC Trial I: Name/D	C trials:  Dose:	Trial Dates:		
Failure reason:				
Preferred DOAC Trial 2: Name/Dose:		Trial Dates:		
Failure reason:				
Requests for edoxaban (Savay	rsa):			
Provide documentation of 5 to 10 or unfractionated heparin) for diag	days of initial therapy with a parenteral gnosis of DVT or PE:	anticoagulant (low	molecular weight heparin	
Drug name & dose:		Trial dates:		
Medical or contraindication reason	n to override trial requirements:			
Attach lab results and other do	cumentation as necessary.			
Prescriber signature (Must match pres	scriber listed above.)	Date of subm	ission	
1				

Score

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Health and Human Services, that the member continues to be eligible for Medicaid.

PAA - 1031 (1/24) Page 2 of 2